Global Cardiomyopathies Market Report to 2031 – Featuring AstraZeneca, Merck, Novartis, Sanofi and Abbott Among Others –

Global Cardiomyopathies Market Report to 2031 – Featuring AstraZeneca, Merck, Novartis, Sanofi and Abbott Among Others –

Global Cardiomyopathies Market Report to 2031 – Featuring AstraZeneca, Merck, Novartis, Sanofi and Abbott Among Others –

DUBLIN–(BUSINESS WIRE)–The “Cardiomyopathies Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031” drug pipelines has been added to’s offering.

The publisher projects the therapeutic market for cardiomyopathies within the 7MM will grow from $1.6B in 2021 at a compound annual growth rate (CAGR) of 12.4% to $5.2B by 2031.

Companies Mentioned

  • AstraZeneca
  • Merck
  • Boehringer Ingelheim
  • Novartis
  • Sanofi
  • Abbott
  • GlaxoSmithKline
  • Bristol Myers Squibb
  • MyoKardia
  • Pfizer
  • Cytokinetics

Main drivers of growth:

  • Camzyos (Bristol Myers Squibb) and aficamten (Cytokinetics) launch across the 7MM
  • Entresto (sacubitril + valsartan) label expansion to include CM

Key Highlights

  • The cardiomyopathies market is currently highly genericized and contains many off-label medications, which provide affordable options with limited side effects. These factors create a stiff barrier for entry of novel therapeutics, but pipeline therapeutics will find success due to strong efficacy and safety profiles and that they are cardiomyopathy-specific therapeutics, rather than general cardiovascular drugs.
  • There is an increased focus on genetic screening and developing genetic therapeutics because cardiomyopathies are often inherited rather than acquired. Emprumapimod will be the first marketed genetic therapy, as it targets patients with DCM due to a lamin gene mutation. However, this drug will not generate significant revenue given the small size of the target patient population.
  • There is not a cure for cardiomyopathies, instead the disease symptoms are managed with generic cardiovascular drugs. This remains an area of unmet need in the cardiomyopathies space.
  • Camzyos was the first novel therapy launched in the cardiomyopathies market in several decades when it was marketed in 2022. Thus, there is a need for novel therapies in this space, which should be met by the extensive pipeline.


  • Overview of cardiomyopathies including epidemiology, disease etiology and management.
  • Topline cardiomyopathy drugs market revenue (including off-label adjunct therapeutics used for metabolic benefits), annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.
  • Key topics covered include assessment of current and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU, and Japan over the 10-year forecast period.
  • Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global cardiomyopathy therapeutics market. Insightful review of the key industry drivers, restraints and challenges.

Reasons to Buy

The report will enable you to:

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global cardiomyopathy therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global cardiomyopathies market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global cardiomyopathy therapeutics market from 2021-2031.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Key Topics Covered:

1 Cardiomyopathies: Executive Summary

2 Introduction

3 Disease Overview

3.1 Etiology and pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

4 Epidemiology

4.1 Disease Background

4.1.1 Risk Factors and Comorbidities

4.2 Global and Historical Trends

4.3 Forecast Methodology

4.4 Epidemiological Forecast for Cardiomyopathies (2021-2031)

4.5 Discussion

5 Disease Management

5.1 Diagnosis and treatment overview

5.2 KOL insights on disease management

6 Competitive Assessment

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Improvements in genetic screening and gene therapies

7.3 Curative rather than preventative therapy options

7.4 Newer drugs with specific targets

7.5 Adequate diagnosis and treatment of amyloid cardiomyopathy patients

8 R&D Strategies

8.1 Overview

8.1.1 Label expansion

8.1.2 Development of drugs with novel targets

8.2 Clinical trial design

8.2.1 Quality of life endpoints

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-making trends

12 Market Outlook

13 Appendix

For more information about this drug pipelines report visit

Source: GlobalData


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900